Edition:
United Kingdom

Hansa Medical AB (HMED.ST)

HMED.ST on Stockholm Stock Exchange

243.00SEK
15 Dec 2017
Change (% chg)

-1.00kr (-0.41%)
Prev Close
244.00kr
Open
245.00kr
Day's High
245.00kr
Day's Low
240.50kr
Volume
86,354
Avg. Vol
159,412
52-wk High
271.50kr
52-wk Low
95.00kr

Summary

Name Age Since Current Position

Birgit Stattin Norinder

69 2017 Chairman of the Board

Ulf Wiinberg

58 2017 Acting Chief Executive Officer

Eva-Maria Joed

48 2015 Chief Financial Officer, Vice President

Christian Kjellman

50 Senior Vice President, Research and Development

Sam Agus

50 2017 Vice President, Chief Medical Officer

Karin Aschan

56 2016 Vice President, Regulatory Affairs

Henk Doude van Troostwijk

52 2016 Vice President, Commercial Operations

Lena Winstedt

48 Vice President, Project Management

Emanuel Bjorne

44 Vice President, Business Development and Investor Relations

Angelica Loskog

44 2016 Director

Stina Gestrelius

68 2007 Independent Director

Hans Schikan

59 2015 Independent Director

Per-Olof Wallstrom

68 2011 Independent Director

Biographies

Name Description

Birgit Stattin Norinder

Ms. Birgit Stattin Norinder has served as Chairman of the Board at Hansa Medical AB since November 8, 2017. She has been Independent Member of the Board of Directors of Hansa Medical AB since May 11, 2016. She was previously Independent Chairman of the Board of Directors at the Company from October 1, 2014 until May 11, 2016. She has been Member of the Company's Board since May 14, 2012. She is Member of the Remuneration Committee and Member of the Audit Committee as well as Chairman of the Scientific Committee of the Company. She has experience from international pharmaceutical and biotechnology companies in Sweden, the United States and the United Kingdom (UK). She has managed several research and development departments. She has also served as Chief Executive Officer and Chairman at Prolifix Ltd., Senior Vice President of Worldwide Product Development at Pharmacia & Upjohn and Dir. Int. Reg. Affairs Division at Glaxo Group Research Ltd. She has also held several Board and Chairman positions at UK, Swedish and Norwegian biotechnology companies. She is Member of the Boards of AddLife AB, Nicox S.A., Wnt Research AB and Jettesta AB. She was Chairman of the Board of Directors of Wingfirm Pharma AB, Partners for Utvecklingsinvesteringar inom Life Sciences, P.U.L.S. AB and Index Pharmaceutical AB, as well as Board Member of Karo Bio Aktiebolag and Antisoma Plc. She holds a Master of Science degree in Pharmacy from Uppsala Universitet (Uppsala University).

Ulf Wiinberg

Mr. Ulf Wiinberg has been Acting Chief Executive Officer of Hansa Medical AB since November 8, 2017. He has previously been Independent Chairman of the Board of Directors of Hansa Medical AB since May 11, 2016. He is an experienced healthcare industry professional who has served the boards of several healthcare industry associations. At Wyeth, he has been both President of the global consumer health care business and President for the European pharma business, and he has also held the position as CEO of H Lundbeck A/S, a pharmaceutical company specialized in psychiatric and neurological disorders, for several years. Ulf is a non-executive Board member at Alfa Laval AB, Agenus Inc, UCB and Sigrid Therapeutics AB. He is also Chairman of Trialbee AB and Avillion. He also serves as CEO and Chairman of Ulf Wiinberg consulting&invest AB.

Eva-Maria Joed

Ms. Eva-Maria Joed has served as Vice President and Chief Financial Officer of Hansa Medical AB since 2015. Eva-Maria joined Hansa Medical in 2015 and has long and wide experience within finance. She has held positions both as Chief Accountant and CFO and worked in international companies such as Kemira Kemi AB, Johns Manville AB within the Berkshire Hathaway group and Procordia Food AB. She has also been responsible for implementing new financial systems and policies, and for IT. Eva-Maria holds a Master of Science in Business and Economics from Lund University.

Christian Kjellman

Dr. Christian Kjellman, Ph.D. serves as Senior Vice President, Research and Development at Hansa Medical AB. He has previously served as Chief Scientific Officer at the Company since 2008. He was previously Senior Scientist at BioInvent AB. Prior to that, he was Head of Research at Cartela AB, mainly focusing on novel drug target evaluation. He has experience as Researcher in Cell and Molecular Biology and as Assistant Professor in Molecular Genetics at Lunds Universitet (Lund University). He holds a Master of Science degree in Chemical Biology and a Doctorate in Philosophy degree in Tumor Immunology, both from Lunds Universitet.

Sam Agus

Dr. Sam Agus, M.D. has been Vice President, Chief Medical Officer at Hansa Medical AB since April 2017. He has a broad experience from the pharmaceutical industry and was most recently Chief Specialist, Medical Affairs Neurology at H. Lundbeck A/S. He has previously held various leading positions at several pharmaceutical companies, including Shire, Solvay Pharmaceuticals and Abbott Laboratories. He is a board-certified neurologist and has extensive experience in medical strategy, multidisciplinary team leadership, medical marketing as well as clinical trial design and product launches. His therapy area expertise includes neurology, psychiatry, gastroenterology, women’s health and rare diseases. Sam is an MD and a board certified neurologist, from the Hadasah University Hospital in Jerusalem, Israel.

Karin Aschan

Ms. Karin Aschan has been Vice President, Regulatory Affairs at Hansa Medical AB since the third quarter of 2016. She has a long experience from working within Regulatory Affairs, initially at Astra Zeneca, and has worked on EU and US projects in all phases through the first clinical study up to marketing phase. Karin has held the position as Head of Regulatory Affairs at Active Biotech and at Clinical Data Care. She has also been working as an independent regulatory consultant. Karin holds a M.Sc. in Pharmacy from Uppsala University.

Henk Doude van Troostwijk

Mr. Henk J. Doude van Troostwijk has served as Vice President, Commercial Operations at Hansa Medical AB since May 12, 2016. He has significant management experience in sales and marketing from the areas of transplantation and orphan drugs. Before joining Hansa Medical in 2016, Henk served as General Manager of European Commercial Operations and Emerging Markets at Raptor Pharmaceuticals, an orphan disease focused global biopharma company based in the US. Prior to that, he held the position of Business Unit Director Oncology and Transplantation at Genzyme Europe BV. Henk holds an MBA from Henley Management College at the University of Reading, UK.

Lena Winstedt

Dr. Lena Winstedt serves as Vice President, Project Management at Hansa Medical AB. She has previously been Clinical Research Director at the Company. She has experience in the clinical development of biopharmaceuticals and small molecules. Prior to joining the Company in 2011, she served as Clinical Project Manager at BioInvent International AB focused on Phase I clinical trials for biopharmaceuticals in Europe and the United States. Prior to that, she was International Clinical Project Manager at Genmab A/S and Clinical Research Associate at H. Lundbeck AB. She holds a Master of Science degree in Molecular Biology from both Lunds Universitet (Lund University) and the University of Glasgow, and a Doctorate in Philosophy degree in Microbiology from Lund University.

Emanuel Bjorne

Mr. Emanuel Bjorne serves as Vice President, Business Development and Investor Relations at Hansa Medical AB. He was Corporate Development Director at the Company from November 25, 2014. He was Chief Executive Officer (CEO) of Hansa Medical AB from 2007 until November 25, 2014. He was previously Scientific Project Manager focused on Business Intelligence and Analysis within Pharmaceuticals, Diagnostics and Analytical Instrumentation at Biolin Scientific. Prior to that, he was Analytical Development Chemist at PolyPeptide Labs, focusing on the development of analytical methods based on Mass Spectrometry and Chromatography for peptide drugs in early clinical stage. Previously, he was Member of the Board at Cartela i Malmo AB, and he was Deputy Member of the Board of Directors and CEO of Hansa Medical Utvecklings AB. He holds a Master of Science degree in Engineering Physics, focusing on Biophysical Chemistry from both Lunds Universitet (Lund University) and the University of California in Santa Barbara, the United States.

Angelica Loskog

Dr. Angelica Loskog has been Member of the Board of Directors of Hansa Medical AB since May 11, 2016. She is Doctor of Philosophy (Faculty of Medicine) and adjunct professor at the Department of Immunology, Genetics and Pathology at Uppsala University. She is scientific advisor to Nexttobe, CEO of Lokon Pharma AB, as well as chairman of Vivolux AB and Repos Pharma AB. She is Member of the Company’s Scientific Committee.

Stina Gestrelius

Dr. Stina Gestrelius has served as Independent Member of the Board of Directors at Hansa Medical AB since August 2007. She is Member of the Company’s Scientific Committee. She has 40 years of experience in the Pharmaceutical and Biotechnology industries. She is Entrepreneur. She previously served as Head of Research at Biora AB and as Deputy Chief Executive Officer (CEO) of Medicon Valley Alliance. She is currently working with evaluation of research and innovation project proposals via the consultancy company SigridScience and has held several board positions of Scandinavian biotechnology companies including BioActive Polymers AB, Bioara AB, Biogaia AB (publ), Clavis Pharma ASA (publ) and Lipopeptide AB. She holds a Master of Science degree in Chemical Engineering and a Doctorate of Philosophy degree in Applied Biochemistry, both from Lunds Universitet (Lund University), as well as a honoris causa Doctorate degree from Malmo hogskola.

Hans Schikan

Mr. Hans GCP Schikan has served as Independent Member of the Board of Directors of Hansa Medical AB since June 2, 2015. He is Member of the Company’s Remuneration and Scientific Committees. He holds Doctorate in Pharmacy degree from the Utrecht University. He has over 25 years of experience from several management positions within the pharmaceutical and biotech industry. He also serves as Chairman of the Board of Asceneuron (Switzerland), Complix (Belgium) and InteRNA Technologies (The Netherlands) and member of the Board of Directors of Sobi and Wilson Therapeutics (Sweden) as well as Therechon (Switzerland). He is also Member of the Core Team of the Dutch Top Sector Life Sciences & Health and adviser to several biotech companies. His past experience includes inter alia CEO of Prosensa (The Netherlands).

Per-Olof Wallstrom

Mr. Per-Olof Wallstrom has served as Independent Member of the Board of Directors at Hansa Medical AB since May 12, 2011. He is Chairman of the Audit Committee of the Company. He has 40 years of experience in various positions within the international Pharmaceutical and Biotechnology industries, including Senior Management positions at Merck, Astra, Pharmacia and Bristol-Myers Squibb. In addition, he served as Chief Executive Officer of Q-Med AB, Melacure Therapeutics AB and Karo Bio AB, as well as Chairman of the Board of Directors at K-B Thorin Arkitektkontor AB, Karo Bio Research AB, Aggal Invest AB and Aros Arkitekter AB, and Member of the Board of Directors at Envirotainer AB, Swedish Orphan Biovitrum International AB and Swedish Orphan Biovitrum Holding AB. He currently acts as Chairman of the Board of Directors at Camurus AB, Board Member and Founder of Arosia Communication AB and Member of the Board of Directors at NeoDynamics AB. He holds a Master of Science degree in Pharmacy from Uppsala Universitet (Uppsala University).